These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21393193)

  • 1. Extreme alkaline phosphatase elevation associated with tigecycline.
    Bonilla MF; Avery RK; Rehm SJ; Neuner EA; Isada CM; van Duin D
    J Antimicrob Chemother; 2011 Apr; 66(4):952-3. PubMed ID: 21393193
    [No Abstract]   [Full Text] [Related]  

  • 2. More about the safety of tigecycline for the treatment of infectious diseases: the role of superinfection rates.
    Martín-Gandul C; García-Cabrera E; Castillo-Ojeda E; Jiménez-Mejías ME
    J Antimicrob Chemother; 2012 Apr; 67(4):1048-9. PubMed ID: 22207597
    [No Abstract]   [Full Text] [Related]  

  • 3. Exposure-response analyses of tigecycline tolerability in healthy subjects.
    Passarell J; Ludwig E; Liolios K; Meagher AK; Grasela TH; Babinchak T; Ellis-Grosse EJ
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):123-9. PubMed ID: 19748422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of tigecycline: focus on use for approved indications.
    Vardakas KZ; Rafailidis PI; Falagas ME
    Clin Infect Dis; 2012 Jun; 54(11):1672-4. PubMed ID: 22431809
    [No Abstract]   [Full Text] [Related]  

  • 5. Tigecycline: a single antibiotic for polymicrobial infections.
    Pankey GA; Steele RW
    Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute necrotizing pancreatitis related to tigecycline.
    Mascarello M; Papa G; Arnez ZM; Luzzati R
    J Antimicrob Chemother; 2012 May; 67(5):1296-7. PubMed ID: 22279181
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections.
    Routsi C; Kokkoris S; Douka E; Ekonomidou F; Karaiskos I; Giamarellou H
    Int J Antimicrob Agents; 2015 Jan; 45(1):90-3. PubMed ID: 25241261
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
    Gardiner D; Dukart G; Cooper A; Babinchak T
    Clin Infect Dis; 2010 Jan; 50(2):229-38. PubMed ID: 20025527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. True incidence of tigecycline-induced pancreatitis: how many cases are we missing?
    Davido B; Shourick J; Makhloufi S; Dinh A; Salomon J
    J Antimicrob Chemother; 2016 Oct; 71(10):2994-5. PubMed ID: 27365188
    [No Abstract]   [Full Text] [Related]  

  • 10. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline-induced acute pancreatitis: case report and literature review.
    Hung WY; Kogelman L; Volpe G; Iafrati M; Davidson L
    Int J Antimicrob Agents; 2009 Nov; 34(5):486-9. PubMed ID: 19540093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline.
    Pieringer H; Schmekal B; Biesenbach G; Pohanka E
    Ann Hematol; 2010 Oct; 89(10):1063-4. PubMed ID: 20174923
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline-induced pancreatitis.
    Lipshitz J; Kruh J; Cheung P; Cassagnol M
    J Clin Gastroenterol; 2009 Jan; 43(1):93. PubMed ID: 18769361
    [No Abstract]   [Full Text] [Related]  

  • 15. Extensive pigmentation secondary to minocycline treatment of rheumatoid arthritis.
    Assad SA; Bernstein EF; Brod B; James WD
    J Rheumatol; 2001 Mar; 28(3):679-82. PubMed ID: 11296985
    [No Abstract]   [Full Text] [Related]  

  • 16. Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database.
    Griffin AT; Harting JA; Christensen DM
    Diagn Microbiol Infect Dis; 2013 Nov; 77(3):273-7. PubMed ID: 24029432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ; Goff DA
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered bioavailability of tacrolimus following intravenous administration of tigecycline.
    Pavan M; Chaudhari AP; Ranganth R
    Am J Kidney Dis; 2011 Feb; 57(2):354. PubMed ID: 21251548
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence for low risk of Clostridium difficile infection associated with tigecycline.
    Wilcox MH
    Clin Microbiol Infect; 2007 Oct; 13(10):949-52. PubMed ID: 17697004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
    Chuang YC; Chang CM; Aradhya S; Nagari B; Pai V; Dartois N; Jouve S; Cooper A
    J Microbiol Immunol Infect; 2011 Apr; 44(2):116-24. PubMed ID: 21439514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.